Virginnio Proost

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction

Tom E. Verstraelen, Freyja H.M. van Lint, Laurens P. Bosman et al. · European Heart Journal · 2021 · 146 citations · Full text

Medicine, Cardiology, Cardiovascular Genetics +14

Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms

Remco de Brouwer, Laura M.G. Meems, Tom E. Verstraelen et al. · Heart Rhythm · 2021 · 17 citations · Full text

Medicine, Cardiology, Genetics +16

Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study

M Heide, Tom E. Verstraelen, Freyja H.M. van Lint et al. · EP Europace · 2024 · 15 citations · Full text

Medicine, Cardiology, Cardiovascular Genetics +16